Drug Profile
CBLB 612
Alternative Names: CBLB-612Latest Information Update: 02 Sep 2021
Price :
$50
*
At a glance
- Originator Cleveland BioLabs
- Developer Statera BioPharma
- Class Chemoprotectants; Proteins
- Mechanism of Action Haematopoietic system modulators; Stem cell modulators; Toll like receptor 2 agonists; Toll like receptor 6 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 01 Sep 2021 Cytocom is now called Statera BioPharma
- 28 Jul 2021 Cytocom has been merged with Cleveland BioLabs to form Cytocom
- 25 Jun 2019 No development reported - Phase-II for Breast cancer (Prevention, Treatment-experienced) in Russia (Parenteral)